Novel BioGlass Fiber Bone Graft: 96.3% Spine Fusion

New Providence, New Jersey-based Prosidyan, Inc. has announced a new study that provides evidence that its bioactive glass fiber-based bone graft substitute can achieve a 96.3% rate of spine fusion.  The multicenter study, “Multi-Center Clinical Evaluation of a Bioactive Fiber-Based Bone Graft Substitute for Posterolateral Fusion” was presented in poster form at the recent American Association of Neurological Surgeons’ (ANNS) Annual Meeting.

The company, which indicated that there were no complications or adverse events related to the device, said that FIBERGRAFT^® BG Matrix is “an ultra-porous synthetic bone graft substitute made from proprietary bioactive glass fibers,” and is “comprised of the clinically-proven FIBERGRAFT^® bioactive glass technology and extra-long fibers of pure type I collagen for flexibility and conformability. In additional to this clinical study, FIBERGRAFT^® BG Matrix has also been evaluated in a preclinical study that showed it to be equivalent to autograft in a challenging rabbit posterolateral spinal fusion model.”

“We are proud of the results achieved in this clinical study and will continue to support the generation of clinical evidence proving the success of our bioactive glass technology in Orthopedic Trauma and Spine surgical procedures. We are motivated to continue to partner with our surgeon customers to assist them in healing patients faster and with fewer complications,” said Charanpreet Bagga, co-founder, president and CEO of Prosidyan, New Providence, New Jersey.

Charanpreet Bagga told OTW, “Since 2009, Prosidyan has been committed to engineering synthetic biomaterials to support clinical needs for bone growth and bone healing. Over the last 12 years, we have developed a robust portfolio of next generation bone grafts and we have several other solutions in our pipeline for multiple clinical needs, including load bearing solutions. Over the last six years, we have started to invest heavily into collecting clinical data related to our products—both retrospective as well as prospective. This recent study is one example of the successful clinical use of our FIBERGRAFT^® BG product line.”